Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease
Abstract Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effect of LCIG on Advanced Parkinson’s Disease (APD) patients QoL. Secondarily...
Gorde:
| Egile Nagusiak: | , , , , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Nature Portfolio
2021-11-01
|
| Saila: | npj Parkinson's Disease |
| Sarrera elektronikoa: | https://doi.org/10.1038/s41531-021-00246-y |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|